Can I Take Melatonin with Rapamycin (Sirolimus)?

How Sirolimus Is Metabolized (and Why That Matters for Drug Interactions)

Sirolimus is cleared almost entirely through CYP3A4-mediated oxidation in the intestinal wall and liver, with P-glycoprotein acting as a co-transporter that governs intestinal absorption. The FDA-approved Rapamune labeling documents that strong CYP3A4 inhibitors such as ketoconazole can raise sirolimus whole-blood concentrations by 11-fold, while strong inducers like rifampin reduce trough levels by roughly 82% [1]. Any co-administered compound that meaningfully inhibits or induces CYP3A4 or P-gp requires a dose adjustment and trough monitoring.

Melatonin does not fit that profile. Its primary metabolic route runs through CYP1A2, with a minor contribution from CYP2C19, and it shows no clinically significant affinity for CYP3A4 or P-gp at standard supplemental doses of 0.5 to 10 mg [2].

Why the Pharmacokinetic Risk Is Low

Because melatonin and sirolimus use different cytochrome P450 enzymes, competitive inhibition at the enzyme level is unlikely at the doses used in practice. A 2003 in vitro panel published in Drug Metabolism and Disposition confirmed that CYP1A2 and CYP3A4 have distinct substrate binding pockets with minimal cross-reactivity at therapeutic concentrations [3]. Clinically, this means a patient taking sirolimus 2 mg once weekly (a common off-label longevity protocol) alongside melatonin 1 to 3 mg at night is not generating a situation where melatonin blocks sirolimus clearance or vice versa.

The P-Glycoprotein Question

Some researchers have examined whether melatonin modulates P-gp expression. A rodent study published in the Journal of Pineal Research found that supraphysiologic melatonin doses (pharmacological, not supplemental) altered intestinal P-gp activity, but the effect required serum melatonin concentrations far exceeding what a 5 mg oral supplement produces in humans [4]. At standard sleep-support doses, P-gp modulation by melatonin is not considered clinically meaningful for sirolimus co-administration.

The Pharmacodynamic Concern: Glucose and Insulin Resistance

This is where the conversation gets more clinically important. Both agents independently affect glucose homeostasis, and sirolimus already carries an FDA boxed-adjacent warning about new-onset diabetes mellitus and hyperglycemia in transplant recipients [1].

How Sirolimus Raises Blood Glucose

MTOR (mechanistic target of rapamycin) inhibition by sirolimus suppresses insulin receptor substrate-1 (IRS-1) signaling downstream of the insulin receptor. The result is reduced GLUT4 translocation to the cell membrane in skeletal muscle and adipose tissue, producing peripheral insulin resistance. In the RAPA/NIA study in mice, sirolimus extended median lifespan by 14% in females and 9% in males but also produced measurable impairment in glucose tolerance at therapeutic doses [5]. Human data from the renal transplant population show that 9 to 16% of sirolimus-treated patients develop new-onset diabetes mellitus within the first year post-transplant, compared with 4 to 8% on azathioprine regimens [6].

The off-label longevity community typically uses intermittent dosing (once-weekly 5 to 6 mg or biweekly protocols) to reduce metabolic side effects, but even intermittent dosing produces transient rises in fasting glucose for 24 to 48 hours after each dose in glucose-sensitive individuals.

How Melatonin Affects Insulin Secretion

Melatonin binds MT1 and MT2 receptors on pancreatic beta cells, where MT1 activation inhibits cAMP and cGMP second messengers, reducing glucose-stimulated insulin secretion [7]. The physiological rationale is straightforward: nocturnal melatonin rise signals the body to enter a fasting state and suppress insulin release during sleep. This mechanism is ordinarily beneficial for circadian glucose regulation, but it becomes relevant when combined with a drug that already impairs insulin signaling.

A genome-wide association study published in Nature Genetics (N=36,610) identified a common gain-of-function variant in the MT2 receptor gene (MTNR1B rs10830963) that associates with higher fasting glucose and a 20 to 29% elevated risk for type 2 diabetes [8]. Carriers of this variant who take exogenous melatonin show further impairment in glucose-stimulated insulin secretion compared to non-carriers [9]. Patients on sirolimus who carry MTNR1B risk alleles may face additive glycemic effects when using supplemental melatonin.

Quantifying the Additive Risk

No randomized controlled trial has directly studied the sirolimus-plus-melatonin combination in humans as of this writing. The pharmacodynamic concern is therefore largely mechanistic and extrapolated from separate lines of evidence. A 2022 meta-analysis in Nutrients (20 RCTs, N=1,007) found that melatonin supplementation was associated with a modest but statistically significant reduction in fasting insulin levels (weighted mean difference -1.61 µIU/mL, 95% CI -2.40 to -0.82, P<0.001) and a small decrease in HOMA-IR [10]. That insulin-lowering effect could theoretically compound the insulin resistance imposed by sirolimus, producing wider glycemic swings.

HealthRX Glucose Risk Stratification Framework for Sirolimus + Melatonin:

| Patient Profile | Combined Risk Level | Recommended Action | |---|---|---| | Normal fasting glucose (<100 mg/dL), no metabolic syndrome | Low | Proceed; monitor fasting glucose at 3 months | | Prediabetes (100 to 125 mg/dL) or HOMA-IR >2.5 | Moderate | Discuss with prescriber; consider melatonin <1 mg; check HbA1c quarterly | | Established T2DM or on insulin/sulfonylurea | High | Requires prescriber sign-off; closer glucose monitoring; consider alternatives | | MTNR1B rs10830963 risk allele carrier (if known) | Moderate-High | Extra caution; CGM monitoring may be appropriate |

Potential Benefits: Does Melatonin Complement Sirolimus in Any Way?

The mechanistic picture is not entirely adverse. A body of preclinical research suggests melatonin may actually support some of the same longevity pathways sirolimus targets, though through different routes.

mTOR Pathway Interaction

Melatonin has been shown to modulate mTOR signaling in cancer cell lines and aging-related tissue models. A 2019 review in Ageing Research Reviews summarized evidence that melatonin can activate AMPK, which is an upstream negative regulator of mTORC1, suggesting a potential additive effect on the same longevity pathway that sirolimus targets [11]. Whether this translates into any meaningful combination in humans on longevity protocols has not been tested in clinical trials.

Antioxidant and Mitochondrial Effects

Sirolimus can increase reactive oxygen species (ROS) production as a side effect of mitochondrial disruption downstream of mTORC1 inhibition. Melatonin is one of the most potent endogenous antioxidants known, with a single melatonin molecule capable of scavenging two hydroxyl radicals and two peroxyl radicals [12]. Some longevity-oriented clinicians prescribe or endorse melatonin (sometimes at pharmacological doses of 10 to 20 mg) alongside sirolimus for this reason. The evidence base for this practice remains preclinical.

Sleep Quality and Indirect Metabolic Benefits

Sirolimus does not directly impair sleep, but some patients on immunosuppressive regimens report disrupted sleep patterns secondary to their underlying condition or other co-medications. Because poor sleep independently drives insulin resistance and cortisol dysregulation, optimizing sleep through low-dose melatonin (0.5 to 1 mg taken 30 to 60 minutes before bed) may indirectly offset some of the metabolic burden of sirolimus therapy. The American Academy of Sleep Medicine guideline on chronic insomnia acknowledges melatonin's role in circadian entrainment, particularly for delayed sleep phase and jet lag, at doses of 0.5 to 5 mg [13].

Timing, Dosing, and Practical Co-Administration Guidance

Separating Doses Appropriately

Because the main risk is pharmacodynamic rather than pharmacokinetic, dose separation does not fully neutralize the concern the way it might for absorption-level interactions. Practical timing still matters.

Sirolimus has a half-life of approximately 62 hours and reaches peak blood levels (T-max) 1 to 3 hours after oral ingestion. Melatonin clears within 4 to 6 hours. Taking sirolimus in the morning (a common practice to mirror diurnal mTOR fluctuation patterns) and melatonin at bedtime creates a natural 10 to 14-hour separation between peak sirolimus absorption and melatonin ingestion. This timing does not eliminate the pharmacodynamic overlap during the first 24 to 48 hours after a sirolimus dose, but it avoids stacking the two peaks simultaneously.

Dose Recommendations for Melatonin

Standard supplemental melatonin doses range from 0.5 mg to 10 mg. Evidence from a 2022 meta-analysis in the Journal of Sleep Research indicates that lower doses (0.5 to 1 mg) are as effective as higher doses for sleep onset, with fewer next-morning grogginess complaints [14]. For patients on sirolimus, the HealthRX clinical team recommends starting at 0.5 mg and not exceeding 3 mg without prescriber review, particularly if fasting glucose is in the prediabetic range.

What to Monitor

Patients combining sirolimus and melatonin should track the following at every 3-month check:

• Fasting plasma glucose (target <100 mg/dL; flag at >126 mg/dL)
• Hemoglobin A1c (target <5.7%; flag at >6.5%)
• Sirolimus whole-blood trough level (target range varies by indication: transplant 4 to 12 ng/mL; off-label longevity protocols commonly aim for 3 to 8 ng/mL)
• Fasting lipid panel (sirolimus independently raises triglycerides and LDL in a subset of patients) [1]

What Clinicians and Guidelines Say

The Natural Medicines Comprehensive Database rates the interaction between melatonin and sirolimus as a "minor" interaction, citing primarily the theoretical pharmacodynamic overlap in glucose regulation rather than a confirmed kinetic interaction.

Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and a prominent figure in the longevity medicine field, has noted in public discussions that adding antioxidant and sleep-support compounds to rapamycin protocols may reduce off-target burden, but he has also consistently emphasized that "the metabolic side effects of rapamycin require active monitoring, not just theoretical reassurance."

The Endocrine Society's 2023 clinical practice guideline on diabetes management in solid organ transplant recipients states: "All patients initiated on mTOR inhibitors should receive baseline and quarterly fasting glucose measurements given the high incidence of new-onset diabetes in this population" [15]. That guideline does not specifically address melatonin supplementation, but its monitoring framework applies directly when any additional glucose-modulating factor is introduced.

Special Populations: Who Should Be Extra Careful?

Patients with Prediabetes or Metabolic Syndrome

If fasting glucose sits between 100 to 125 mg/dL at baseline, sirolimus alone carries a meaningful risk of pushing that into the diabetic range. Adding melatonin's beta-cell suppression on top of sirolimus-mediated peripheral insulin resistance requires a careful prescriber conversation before proceeding.

Older Adults

Melatonin secretion naturally declines with age, so many longevity-focused patients taking sirolimus are also older adults seeking to replenish melatonin. Older kidneys clear sirolimus more slowly, and hepatic CYP3A4 activity decreases by roughly 20 to 30% between age 40 and age 70 [16], meaning sirolimus troughs may be higher than expected. Starting both agents together in a patient over 65 without established trough monitoring is not advisable.

Post-Transplant Patients

Patients taking sirolimus for immunosuppression (typically 2 to 5 mg daily) have far higher and more sustained drug exposure than individuals on weekly longevity protocols. Any supplemental addition should be reviewed by the transplant pharmacist and physician. In this group, even indirect glucose effects carry higher stakes because immunosuppressive regimens already include corticosteroids, which further drive hyperglycemia.

Summary of the Interaction Profile

The sirolimus-melatonin combination does not carry the kind of high-alert pharmacokinetic interaction seen with, say, sirolimus and fluconazole (which raises sirolimus AUC by 169%) [1]. The enzyme pathways are different, the half-lives are starkly different, and no clinical case series documents harmful blood level changes from co-administration.

The pharmacodynamic story demands more respect. Sirolimus suppresses insulin signaling at the IRS-1 level. Melatonin suppresses insulin secretion at the pancreatic beta cell. Together, they could narrow the glycemic safety margin in patients who already have suboptimal glucose tolerance. The magnitude of this combined effect in healthy individuals on low-dose intermittent sirolimus is probably small, but it is not zero.

A graded approach works best: confirm baseline metabolic labs, start melatonin at 0.5 mg at bedtime, take sirolimus in the morning, and recheck fasting glucose and HbA1c at the 3-month mark. If fasting glucose exceeds 110 mg/dL on two consecutive measurements, reassess whether melatonin is contributing and discuss the finding with your prescriber.